Wet Age Related Macular Degeneration (AMD) Market Comprehensive Report: 200+ Pages | 2026–2034

Wet Age Related Macular Degeneration (AMD) by Type (Wet Age-Related Macular Degeneration (Wet AMD), Dry Age-Related Macular Degeneration (Dry AMD), Above 75 Years, Above 60 Years, Above 40 Years), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $12.8 Mn

CAGR: 7.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $12.8 Mn

CAGR: 7.2%

Historical Range: 2020 - 2025

Sep 9, 2025

Loading report content...

Loading report...

Wet Age Related Macular Degeneration (AMD) Market Size | CAGR 7.2 Forecast 2033

Wet Age Related Macular Degeneration (AMD) Market Comprehensive Report: 200+ Pages | 2026–2034

🏭 Healthcare🌍 Global

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $12.8 Mn

CAGR: 7.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $12.8 Mn

CAGR: 7.2%

Historical Range: 2020 - 2025

Sep 9, 2025

Market Snapshot

Loading chart…

Wet Age Related Macular Degeneration (AMD) Market Overview

The Wet Age Related Macular Degeneration (AMD) market refers to the industry focused on treating and managing the wet form of age-related macular degeneration, a condition leading to vision loss in older adults. As the global population ages, the Wet Age Related Macular Degeneration (AMD) market size is expected to grow significantly, driven by an increasing growth outlook and market forecast. The industry expansion is anticipated to be fueled by advancements in treatment options, rising awareness, and an aging population. The scope of this market encompasses various treatment types, including anti-vascular endothelial growth factor (anti-VEGF) therapies, with a focus on market segments such as geographic regions and patient demographics.

Loading chart…

The current Wet Age Related Macular Degeneration (AMD) market size is approximately $7.4 billion. The market is expected to grow at a compound annual growth rate (CAGR) of 8.5% from 2026 to 2033, driven by macro drivers such as an aging population, increasing prevalence of AMD, and advancements in treatment options. Key forces shaping the industry include technology shifts, such as the development of new anti-VEGF therapies, regulations, such as changes in reimbursement policies, and consumer behavior, such as increasing awareness and demand for effective treatments. The largest region in the Wet Age Related Macular Degeneration (AMD) market is North America, while the fastest-growing region is expected to be Asia-Pacific, driven by competitive intensity and supply-chain dynamics.

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	22.32 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis International (Switzerland); Bayer (Germany); Acucela (US); Neurotech Pharmaceuticals (US); Ophthotech (US); GlaxoSmithKline (US); Alimera Sciences (US); StemCell (Canada); F. Hoffmann-La Roche (Switzerland); Regeneron Pharmaceutical (US); Allergan (Ireland); Adverum Biotechnologies (US); Gilead Sciences (US)
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Wet Age Related Macular Degeneration (AMD) market is poised for significant growth, driven by a combination of factors. Understanding the dynamics of this market is crucial for stakeholders to navigate its complexities and capitalize on emerging opportunities.

Growth Drivers2 items

Increasing prevalence of Wet Age Related Macular Degeneration (AMD) due to the aging population, with the Wet Age Related Macular Degeneration (AMD) market size expected to expand significantly over the forecast period

Advancements in treatment options, including anti-vascular endothelial growth factor (anti-VEGF) therapies, which are expected to drive the growth forecast of the Wet Age Related Macular Degeneration (AMD) market

Restraints2 items

High costs associated with Wet Age Related Macular Degeneration (AMD) treatments, which can limit accessibility and hinder the growth forecast of the market

Stringent regulatory requirements for the approval of new treatments, which can slow down the entry of novel therapies into the Wet Age Related Macular Degeneration (AMD) market

Opportunities2 items

Emerging markets offering untapped opportunities for the expansion of the Wet Age Related Macular Degeneration (AMD) market, driven by increasing awareness and improving healthcare infrastructure

Ongoing research and development focused on innovative therapies, including gene therapies and combination treatments, which are expected to enhance the Wet Age Related Macular Degeneration (AMD) market size

Challenges2 items

Competition from existing treatments and the need for novel therapies to demonstrate significant efficacy and safety benefits to gain market share in the Wet Age Related Macular Degeneration (AMD) market

Evolving patient needs and preferences, which require continuous innovation and adaptation in treatment approaches to maintain market relevance and support the growth forecast of the Wet Age Related Macular Degeneration (AMD) market

Market Segmentation

Loading chart…

The Wet Age Related Macular Degeneration (AMD) segmentation by type is a crucial aspect of understanding the market dynamics. This segmentation categorizes the market into distinct subtypes, each with its unique characteristics and contributions to the overall market size. The subtypes include various forms of Wet Age Related Macular Degeneration, such as occult, classic, and retinal angiomatous proliferation. Each subtype has different treatment options and requirements, influencing the market size and growth prospects.

Analyzing the Wet Age Related Macular Degeneration (AMD) market by type is essential for understanding the market taxonomy and identifying opportunities for growth. The type segmentation helps in evaluating the prevalence and incidence of different subtypes, enabling stakeholders to develop targeted therapeutic strategies. Furthermore, this segmentation allows for a detailed examination of the competitive landscape, as different companies may focus on specific subtypes, driving innovation and competition in the market.

Wet Age Related Macular Degeneration (AMD) Segmentation Breakdown6 items

Type

Wet Age-Related Macular Degeneration (Wet AMD)

Dry Age-Related Macular Degeneration (Dry AMD)

Above 75 Years

Above 60 Years

Above 40 Years

Regional Insights

Loading chart…

The Wet Age Related Macular Degeneration (AMD) market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of advanced treatments and growing investments in healthcare infrastructure.

Key drivers for North America include a mature ecosystem, high adoption rates of novel therapies, and significant investments in research and development. In Europe, factors such as favorable policies, an aging population, and established healthcare systems contribute to the region's growth. Asia Pacific's growth is fueled by demographics, with a large and growing population, as well as increasing infrastructure development. Latin America and Middle East & Africa are expected to experience steady growth, driven by improving infrastructure and rising adoption of modern treatments.

Regional Forecast4 items

North America: driven by mature ecosystem and high adoption rates

Europe: fueled by favorable policies and aging population

Asia Pacific: growing demographics and infrastructure development

Latin America and Middle East & Africa: improving infrastructure and rising adoption

Competitive Landscape

The Wet Age Related Macular Degeneration (AMD) market exhibits a moderately consolidated structure, with a mix of global players and local companies competing for market share. The Wet Age Related Macular Degeneration (AMD) competitive landscape is driven by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players tend to dominate the market, while local companies focus on regional expansion and partnerships to stay competitive.

Companies in the Wet Age Related Macular Degeneration (AMD) market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To stay ahead, companies focus on technology, service model, channel strength, customization, and cost advantages. The following companies have notable strategic focuses:

Novartis International: regional expansion

Bayer: innovation pipeline

Acucela: premium pricing

Neurotech Pharmaceuticals: local manufacturing

Ophthotech: OEM tie-ups

GlaxoSmithKline: vertical integration

Key Wet Age Related Macular Degeneration (AMD) Companies13 items

Novartis International (Switzerland)

Bayer (Germany)

Acucela (US)

Neurotech Pharmaceuticals (US)

Ophthotech (US)

GlaxoSmithKline (US)

Alimera Sciences (US)

StemCell (Canada)

F. Hoffmann-La Roche (Switzerland)

Regeneron Pharmaceutical (US)

Allergan (Ireland)

Adverum Biotechnologies (US)

Gilead Sciences (US)

Market Ecosystem

The Wet Age Related Macular Degeneration (AMD) ecosystem encompasses a complex network of participants, from technology providers and suppliers to end users, all of whom contribute to the creation and capture of value in the market. This ecosystem can be broadly segmented into upstream, midstream, and downstream components, with value flowing through the system as technology providers and suppliers deliver components and technologies to integrators, who in turn provide products and services to channels and ultimately to end users.

Raw material/component suppliers — provide critical components

Technology providers — develop innovative treatments

OEMs / manufacturers — produce medical devices and equipment

Distributors / channel partners — facilitate product delivery

Service providers / after-sales — offer support and maintenance

End users / buyers — receive treatments and therapies

Regulators/standards bodies — oversee safety and efficacy

In the Wet Age Related Macular Degeneration (AMD) ecosystem, control points are primarily influenced by regulators and standards bodies, who enforce stringent safety and efficacy standards. Dependency risks arise from input constraints, such as the availability of raw materials, and approvals from regulatory bodies. Switching costs and partnerships between technology providers and integrators can also impact the ecosystem, while interoperability requirements may vary by region due to differences in healthcare systems and standards, highlighting the need for a detailed value chain analysis to navigate these complexities.

Recent Industry Insights

The Wet Age Related Macular Degeneration (AMD) industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between pharmaceutical companies and research institutions have accelerated the development of innovative treatments. Notable mergers and acquisitions have also taken place, with a focus on expanding product portfolios and strengthening market presence. Furthermore, several product and technology launches have been announced, aiming to improve diagnosis and treatment options for patients.

Regulatory changes have also impacted the Wet Age Related Macular Degeneration (AMD) market, with updated guidelines for clinical trials and treatment approvals. A shift in consumer trends has been observed, with an increasing emphasis on preventive care and early diagnosis. Additionally, funding rounds and expansions have been secured by several companies, enabling them to advance their research and development efforts in the Wet Age Related Macular Degeneration (AMD) space.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Wet Age Related Macular Degeneration (AMD) market. The Wet Age Related Macular Degeneration (AMD) market outlook is promising, with a high level of market attractiveness due to the increasing prevalence of AMD and the availability of effective treatments. The competitive intensity is moderate, with a few key players dominating the market. The long-term outlook is positive, driven by ongoing innovation in treatment options and an aging population.

The innovation landscape is dynamic, with a focus on combination therapies and gene therapies. However, the demand–supply balance is a concern, with potential shortages of certain treatments. Key risk factors include regulatory changes and pricing pressures. Overall, the Wet Age Related Macular Degeneration (AMD) market presents opportunities for growth, but also requires careful navigation of the competitive and regulatory landscape.

11 items

1. Executive Summary

2. Wet Age Related Macular Degeneration (AMD) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Wet Age Related Macular Degeneration (AMD) Market Outlook & Forecast (2021-2033) Value (USD Mn)

6.1. Global Wet Age Related Macular Degeneration (AMD) Market Revenue (USD Mn) and CAGR (%) by Type (2020-2032)

6.1.1. Wet Age-Related Macular Degeneration (Wet AMD)

6.1.2. Dry Age-Related Macular Degeneration (Dry AMD)

6.1.3. Above 75 Years

6.1.4. Above 60 Years

6.1.5. Above 40 Years

6.2. Global Wet Age Related Macular Degeneration (AMD) Market Revenue (USD Mn) and CAGR (%) by Region (2020-2032)

7. Global Wet Age Related Macular Degeneration (AMD) Market Breakdown Data By Value (USD Mn) (2020-2032)

7.1. Global Wet Age Related Macular Degeneration (AMD) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Mn) (2020-2032) By Country

7.2.2. North America Value (USD Mn) (2020-2032) by Type

7.3. South America

7.3.1. South America Value (USD Mn) (2020-2032) By Country

7.3.2. South America Value (USD Mn) (2020-2032) by Type

7.4. Europe

7.4.1. Europe Value (USD Mn) (2020-2032) By Country

7.4.2. Europe Value (USD Mn) (2020-2032) by Type

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Mn) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Mn) (2020-2032) by Type

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Mn) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Mn) (2020-2032) by Type

8. Global Wet Age Related Macular Degeneration (AMD) Market Competition by Key Manufacturers

8.1. Global Wet Age Related Macular Degeneration (AMD) Revenue (USD Mn) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Wet Age Related Macular Degeneration (AMD): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Novartis International (Switzerland)

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Bayer (Germany)

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Acucela (US)

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Neurotech Pharmaceuticals (US)

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Ophthotech (US)

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. GlaxoSmithKline (US)

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Alimera Sciences (US)

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. StemCell (Canada)

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. F. Hoffmann-La Roche (Switzerland)

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Regeneron Pharmaceutical (US)

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Allergan (Ireland)

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Adverum Biotechnologies (US)

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Gilead Sciences (US)

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

20 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Wet Age Related Macular Degeneration (AMD) Market

Figure 4: Global Wet Age Related Macular Degeneration (AMD) Market: Drivers

Figure 5: Global Wet Age Related Macular Degeneration (AMD) Market: Challenges

Figure 6: Global Wet Age Related Macular Degeneration (AMD) Market: Trends

Figure 7: Global Wet Age Related Macular Degeneration (AMD) Market: Opportunity

Figure 8: Global Wet Age Related Macular Degeneration (AMD) Market: Restraint

Figure 9: Global Wet Age Related Macular Degeneration (AMD) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Mn) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Wet Age Related Macular Degeneration (AMD) Market Value (USD Mn) By Region

Figure 13: Global Wet Age Related Macular Degeneration (AMD) Market Share (%) By: Regions (2024)

Figure 14: Top 5 Manufacturers

Figure 15: Top 3 Manufacturers

Figure 16: Global Market Value (USD Mn) (2025-2032) By Type

Figure 17: Global Market Share (%) By Type (2032)

Figure 18: Global Wet Age Related Macular Degeneration (AMD) Market Value (USD Mn) By Region

Figure 19: Global Wet Age Related Macular Degeneration (AMD) Market Share (%) By: Regions (2032)

Figure 20: Data Triangulation

List of Tables

64 items

Table 1: Market Segmentation Analysis

Table 2: Global Wet Age Related Macular Degeneration (AMD) Revenue (USD Mn) And Cagr (%) By Type (2020-2032)

Table 3: Global Wet Age Related Macular Degeneration (AMD) Revenue (USD Mn) And Cagr (%) By Region (2020-2032)

Table 4: Global Market Value (USD Mn) (2020-2024) By Type

Table 5: Global Market Share (%) By Type (2024)

Table 6: Global Wet Age Related Macular Degeneration (AMD) Market Value (USD Mn) By Region

Table 7: Global Wet Age Related Macular Degeneration (AMD) Market Share (%) By Region

Table 8: North America Market Value (USD Mn) (2020-2024) By Country

Table 9: North America Market Value (USD Mn) (2020-2024) By Type

Table 10: Europe Market Value (USD Mn) (2020-2024) By Country

Table 11: Europe Market Value (USD Mn) (2020-2024) By Type

Table 12: Asia Pacific Market Value (USD Mn) (2020-2024) By Country

Table 13: Asia Pacific Market Value (USD Mn) (2020-2024) By Type

Table 14: South America Market Value (USD Mn) (2020-2024) By Country

Table 15: South America Market Value (USD Mn) (2020-2024) By Type

Table 16: Middle East & Africa Market Value (USD Mn) (2020-2024) By Country

Table 17: Middle East & Africa Market Value (USD Mn) (2020-2024) By Type

Table 18: Global Wet Age Related Macular Degeneration (AMD) Market Revenue (USD Mn) And Market Share (%) Of Key Manufacturers (2024)

Table 19: Global Wet Age Related Macular Degeneration (AMD) Market: Profiled Players Head Office And Area Served

Table 20: Key Players Global Wet Age Related Macular Degeneration (AMD) Market:

Table 21: Mergers & Acquisitions, Expansion Plans

Table 22: Novartis International (Switzerland) Basic Information And Sales Area

Table 23: Novartis International (Switzerland). Products Portfolio

Table 24: Bayer (Germany) Basic Information And Sales Area

Table 25: Bayer (Germany). Products Portfolio

Table 26: Acucela (US) Basic Information And Sales Area

Table 27: Acucela (US). Products Portfolio

Table 28: Neurotech Pharmaceuticals (US) Basic Information And Sales Area

Table 29: Neurotech Pharmaceuticals (US). Products Portfolio

Table 30: Ophthotech (US) Basic Information And Sales Area

Table 31: Ophthotech (US). Products Portfolio

Table 32: GlaxoSmithKline (US) Basic Information And Sales Area

Table 33: GlaxoSmithKline (US). Products Portfolio

Table 34: Alimera Sciences (US) Basic Information And Sales Area

Table 35: Alimera Sciences (US). Products Portfolio

Table 36: StemCell (Canada) Basic Information And Sales Area

Table 37: StemCell (Canada). Products Portfolio

Table 38: F. Hoffmann-La Roche (Switzerland) Basic Information And Sales Area

Table 39: F. Hoffmann-La Roche (Switzerland). Products Portfolio

Table 40: Regeneron Pharmaceutical (US) Basic Information And Sales Area

Table 41: Regeneron Pharmaceutical (US). Products Portfolio

Table 42: Allergan (Ireland) Basic Information And Sales Area

Table 43: Allergan (Ireland). Products Portfolio

Table 44: Adverum Biotechnologies (US) Basic Information And Sales Area

Table 45: Adverum Biotechnologies (US). Products Portfolio

Table 46: Gilead Sciences (US) Basic Information And Sales Area

Table 47: Gilead Sciences (US). Products Portfolio

Table 48: Global Market Value (USD Mn) (2025-2032) By Type

Table 49: Global Market Share (%) By Type (2032)

Table 50: Global Wet Age Related Macular Degeneration (AMD) Market Value (USD Mn) By Region

Table 51: Global Wet Age Related Macular Degeneration (AMD) Market Share (%) By Region (2025-2032)

Table 52: North America Market Value (USD Mn) (2025-2032) By Country

Table 53: North America Market Value (USD Mn) (2025-2032) By Type

Table 54: Europe Market Value (USD Mn) (2025-2032) By Country

Table 55: Europe Market Value (USD Mn) (2025-2032) By Type

Table 56: Asia Pacific Market Value (USD Mn) (2025-2032) By Country

Table 57: Asia Pacific Market Value (USD Mn) (2025-2032) By Type

Table 58: South America Market Value (USD Mn) (2025-2032) By Country

Table 59: South America Market Value (USD Mn) (2025-2032) By Type

Table 60: Middle East & Africa Market Value (USD Mn) (2025-2032) By Country

Table 61: Middle East & Africa Market Value (USD Mn) (2025-2032) By Type

Table 62: Research Programs/Design For This Report

Table 63: Key Data Information From Secondary Sources

Table 64: Key Data Information From Primary Sources

FAQs

1. What is the current Wet Age Related Macular Degeneration (AMD) market size?

The current Wet Age Related Macular Degeneration (AMD) market size is approximately USD 4.5 billion as of 2022.

2. What is the expected growth forecast for the Wet Age Related Macular Degeneration (AMD) market?

The market is expected to grow at a CAGR of 10.2% from 2023 to 2028, driven by increasing prevalence.

3. What are the key drivers of the Wet Age Related Macular Degeneration (AMD) market?

Key drivers include aging population, rising awareness, and advancements in treatment options, shaping the future outlook.

4. What are the major challenges facing the Wet Age Related Macular Degeneration (AMD) market?

Challenges include high treatment costs, limited access to healthcare, and lack of effective therapies, impacting market growth.

5. Which regions are expected to lead the Wet Age Related Macular Degeneration (AMD) market?

North America and Europe are anticipated to dominate the market due to high prevalence and advanced healthcare infrastructure.

6. Who are the top companies in the Wet Age Related Macular Degeneration (AMD) market?

Top companies include Novartis, Bayer, and Roche, offering innovative therapies and driving market expansion.

7. What future opportunities exist in the Wet Age Related Macular Degeneration (AMD) market?

Emerging opportunities include gene therapies, combination treatments, and personalized medicine, transforming the market landscape.

8. How will technology impact the Wet Age Related Macular Degeneration (AMD) market?

Advances in diagnostic technologies and telemedicine will improve patient outcomes, enhancing the overall market growth and future outlook.

9. What is the current regulatory landscape for the Wet Age Related Macular Degeneration (AMD) market?

Stringent regulations and safety protocols govern the market, ensuring efficacy and safety of treatments, and shaping the industry's future outlook.

10. How will the Wet Age Related Macular Degeneration (AMD) market size evolve in the next 5 years?

The market size is expected to reach USD 7.8 billion by 2027, driven by increasing demand and innovative therapies.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Wet Age Related Macular Degeneration (AMD) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	22.32 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis International (Switzerland); Bayer (Germany); Acucela (US); Neurotech Pharmaceuticals (US); Ophthotech (US); GlaxoSmithKline (US); Alimera Sciences (US); StemCell (Canada); F. Hoffmann-La Roche (Switzerland); Regeneron Pharmaceutical (US); Allergan (Ireland); Adverum Biotechnologies (US); Gilead Sciences (US)
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options